X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ACTAVIS (US) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ACTAVIS
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ACTAVIS
Dec-14
NOVARTIS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs75819,612-   
Low Rs57911,962-   
Sales per share (Unadj.) Rs228.43,531.5-  
Earnings per share (Unadj.) Rs31.7-440.7-  
Cash flow per share (Unadj.) Rs32.8324.0-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.17,659.7-  
Shares outstanding (eoy) m24.69265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.5 65.5%   
Avg P/E ratio x21.1-35.8 -58.8%  
P/CF ratio (eoy) x20.448.7 41.9%  
Price / Book Value ratio x2.22.1 109.2%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5054,197,775 0.4%   
No. of employees `0000.721.6 3.1%   
Total wages/salary Rs m1,4450-   
Avg. sales/employee Rs Th8,441.343,473.5 19.4%   
Avg. wages/employee Rs Th2,163.60-   
Avg. net profit/employee Rs Th1,173.1-5,425.0 -21.6%   
INCOME DATA
Net Sales Rs m5,639939,027 0.6%  
Other income Rs m1,718-2,344 -73.3%   
Total revenues Rs m7,357936,684 0.8%   
Gross profit Rs m-63120,631 -0.1%  
Depreciation Rs m25203,334 0.0%   
Interest Rs m5529,619 0.2%   
Profit before tax Rs m1,575-114,665 -1.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,411 0.0%   
Tax Rs m792-5,895 -13.4%   
Profit after tax Rs m784-117,181 -0.7%  
Gross profit margin %-1.112.8 -8.6%  
Effective tax rate %50.35.1 977.5%   
Net profit margin %13.9-12.5 -111.4%  
BALANCE SHEET DATA
Current assets Rs m9,522494,747 1.9%   
Current liabilities Rs m3,296360,816 0.9%   
Net working cap to sales %110.414.3 774.1%  
Current ratio x2.91.4 210.7%  
Inventory Days Days3758 63.1%  
Debtors Days Days2866 42.9%  
Net fixed assets Rs m46114,665 0.0%   
Share capital Rs m1230-   
"Free" reserves Rs m7,2130-   
Net worth Rs m7,3362,036,716 0.4%   
Long term debt Rs m01,067,279 0.0%   
Total assets Rs m11,1053,732,629 0.3%  
Interest coverage x29.5-2.9 -1,026.9%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.50.3 201.8%   
Return on assets %7.6-2.3 -322.0%  
Return on equity %10.7-5.8 -185.6%  
Return on capital %22.2-3.0 -738.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,5700-   
CASH FLOW
From Operations Rs m1,610161,249 1.0%  
From Investments Rs m687-386,092 -0.2%  
From Financial Activity Rs m-2,677216,928 -1.2%  
Net Cashflow Rs m-380-7,915 4.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare NOVARTIS With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: AJANTA PHARMA  SUN PHARMA  PANACEA BIOTECH  UNICHEM LAB  AUROBINDO PHARMA  



Today's Market

Indian Indices End Week Strong, Pharma Stocks Show Uptick(Pre-Open)

On Friday, share markets in India opened on a positive note and ended the day in green after a volatile day of trading.

Related Views On News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 16, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS